Rigel Pharmaceuticals (RIGL) EBITDA (2010 - 2026)

Rigel Pharmaceuticals' EBITDA history runs 17 years deep, the most recent figure standing at $11.9 million for Q1 2026.

• In Q1 2026, EBITDA fell 6.95% year-over-year to $11.9 million; the TTM figure through Mar 2026 stood at $124.6 million (up 183.58% YoY), while the FY2025 annual figure was $125.5 million, up 418.63% from the prior year.
• EBITDA was $11.9 million for Q1 2026 at Rigel Pharmaceuticals, down from $23.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $61.1 million in Q2 2025 to a low of -$26.3 million in Q1 2022.
• Historically, EBITDA has averaged $5.0 million across 5 years, with a median of $2.0 million in 2023.
• The sharpest annual moves came in 2022 and 2025: EBITDA plunged 162.89% in 2022, then jumped 13569.57% in 2025.
• A 5-year view of EBITDA shows it stood at $2.1 million in 2022, then slipped by 5.44% to $2.0 million in 2023, then surged by 747.15% to $16.7 million in 2024, then surged by 39.12% to $23.2 million in 2025, then sank by 48.71% to $11.9 million in 2026.
• The last three EBITDA figures came in at $11.9 million (Q1 2026), $23.2 million (Q4 2025), and $28.4 million (Q3 2025), per Business Quant data.